Lung Cancer Update

Featuring a slide presentation from Dr Julia Rotow, including the following topics:Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)CME information and select publications

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)EGFR Mutations (2:23)HER2 Alterations (22:40)Available and Investigational Immunotherapies (32:14)Small Cell Lung Cancer (40:48)CME information and select publications

Featuring an interview with Dr Alexander E Drilon, including the following topics:Overview of targetable biomarkers in lung cancer (0:00)Biomarker testing for genomic alterations in lung cancer (5:24)Overview of ROS1 alterations in lung cancer (13:44)Efficacy data with ROS1 inhibitors for lung cancer (17:02)Safety data with ROS1 inhibitors for lung cancer (21:15)Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)NCPD information and select publications

Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:Introduction (0:00)Best Option for Your Patient (1:28)Biological Considerations (6:26)KRAS G12C Inhibitors (11:33)Second-Line Treatment (13:02)Current Clinical Trials in the First-Line Metastatic Setting (32:18)Current Clinical Trials in the Localized Setting (49:52)Current Clinical Trials with New Treatment Combinations and Agents (53:51)CME information and select publications

Featuring an interview with Prof Ticiana Leal, including the following topics:Pathophysiology and clinical signs and symptoms (0:00)Screening and/or diagnostic approaches (5:45)Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36)Key clinical trial data for amifampridine and practicalities of its administration (14:05)Building awareness among patients, caregivers and the oncology community (22:37)Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35)Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41)Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55)Current research and potential developments in the treatment of SCLC (48:32)CME information and select publications